Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) EBIAT (2016 - 2026)

Akebia Therapeutics has reported EBIAT over the past 10 years, most recently at -$12.2 million for Q4 2025.

  • Quarterly EBIAT rose 46.31% to -$12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 92.3% year-over-year, with the annual reading at -$5.3 million for FY2025, 92.3% up from the prior year.
  • EBIAT was -$12.2 million for Q4 2025 at Akebia Therapeutics, down from $540000.0 in the prior quarter.
  • Over five years, EBIAT peaked at $29.4 million in Q2 2022 and troughed at -$83.0 million in Q2 2021.
  • The 5-year median for EBIAT is -$16.2 million (2023), against an average of -$25.1 million.
  • Year-over-year, EBIAT soared 135.46% in 2022 and then tumbled 3814.01% in 2024.
  • A 5-year view of EBIAT shows it stood at -$69.9 million in 2021, then skyrocketed by 91.31% to -$6.1 million in 2022, then skyrocketed by 110.11% to $614000.0 in 2023, then tumbled by 3814.01% to -$22.8 million in 2024, then soared by 46.31% to -$12.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBIAT are -$12.2 million (Q4 2025), $540000.0 (Q3 2025), and $247000.0 (Q2 2025).